La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).

HH is caused by a genetic mutation that results in deficiency or insensitivity of hepcidin, a hormone that regulates iron absorption and accumulation. There are currently no FDA-approved therapies for HH; the current standard treatment is blood removal via phlebotomy.

The interim analysis included 26 patients who have reached the end of the 16-week treatment period with LJPC-401, a formulation of synthetic human hepcidin. Patients reported a mean reduction in transferrin saturation of 42% compared to placebo-treated patients, who had a mean reduction of 6%.

“There have been no new treatment modalities introduced for patients with hereditary hemochromatosis in more than a decade,” said Dr. Jeff Vacirca, an investigator in the study.

“In light of the negative impact that repeated phlebotomy procedures have on patient quality-of-life, patients would welcome a pharmacologic treatment that they can self-administer and that addresses the underlying pathophysiology of the disease,” he added.

La Jolla expects to announce topline results of this study in the second half of 2019.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.